title: The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy.
abstract: OBJECTIVE
  To compare the effect of gatifloxacin and moxifloxacin on visual outcomes after photorefractive keratectomy (PRK).
  
  
  METHODS
  Thirty-five PRK patients were treated postoperatively with gatifloxacin (Zymar) in one eye and moxifloxacin (Vigamox) in the fellow eye. Postoperative regimens were otherwise identical. In a previous study (initial phase), we evaluated epithelial healing. In this study (second phase), we compared uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), manifest spherical equivalent (MSE), and corneal haze at 6 months postoperatively for 32 patients using the Wilcoxon signed ranks test.
  
  
  RESULTS
  No statistically significant difference was noted between eyes treated with Zymar and Vigamox in terms of UCVA, BSCVA, MSE, or corneal haze at 6 months postoperatively. Two (6%) Vigamox-treated eyes versus 0 (0%) Zymar-treated eyes lost one line of BSCVA from preoperative examination. Median UCVA and MSE were equivalent for both groups.
  
  
  CONCLUSIONS
  At 6 months after PRK, there was no significant difference in visual outcomes with either antibiotic.
authors: Department of Ophthalmology, Georgetown University/Washington Hospital Center, Washington, DC, USA. burkaj@georgetown.edu
authors: Jenna M
authors: JM
authors: Burka
authors: Kraig S
authors: KS
authors: Bower
authors: R Cameron
authors: RC
authors: VanRoekel
authors: Richard D
authors: RD
authors: Stutzman
authors: Chrystyna R
authors: CR
authors: Kuzmowych
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D003318:Corneal Opacity / Q000209:etiology / Q000503:physiopathology; D004311:Double-Blind Method; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005500:Follow-Up Studies; D000077734:Gatifloxacin; D006801:Humans; D054018:Lasers, Excimer; D000077266:Moxifloxacin; D018903:Photorefractive Keratectomy / Q000009:adverse effects; D011182:Postoperative Care; D011184:Postoperative Period; D011804:Quinolines / Q000627:therapeutic use*; D012029:Refraction, Ocular; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity; D014945:Wound Healing
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077734:Gatifloxacin; D000077266:Moxifloxacin